Sernova Biotherapeutics Inc (TSX:SVA)

Sernova Biotherapeutics Balance Sheet

Financials in millions CAD. Fiscal year is November - October.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jan 31, 2026	Oct 31, 2025	Oct 31, 2024	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021
Cash & Equivalents	0.58	0.27	6.01	8.72	3.78	27.87
Short-Term Investments	-	-	-	11.08	46	-
Cash & Short-Term Investments	0.58	0.27	6.01	19.81	49.78	27.87
Cash Growth	-52.28%	-95.59%	-69.64%	-60.21%	78.57%	605.78%
Accounts Receivable	0.13	0.12	0.3	1.05	1.15	0.45
Other Current Assets	0.07	0.14	0.16	0.16	0.17	0
Total Current Assets	0.78	0.52	6.47	21.02	51.09	28.33
Net Property, Plant & Equipment	0.01	0.02	0.83	0.51	0.65	0.56
Other Intangible Assets	-	-	-	0.32	0.52	0.72
Other Long-Term Assets	0.22	0.22	0.22	0.26	0.22	0.21
Total Assets	1.01	0.76	7.53	22.11	52.48	29.82
Accounts Payable	21.67	21.07	19.91	9.46	4.6	1.36
Short-Term Debt	3.86	3.73	-	-	-	-
Current Portion of Leases	-	-	0.1	0.14	0.14	0.12
Total Current Liabilities	25.54	24.8	20.02	9.59	4.74	1.48
Long-Term Debt	1.08	1.04	-	-	-	-
Long-Term Leases	-	-	0.47	-	0.14	0.28
Total Long-Term Liabilities	1.08	1.04	0.47	-	0.14	0.28
Total Liabilities	26.61	25.84	20.48	9.59	4.88	1.75
Common Stock	119.98	118.7	116.68	110.99	110.99	74.01
Additional Paid-in Capital	22.86	22.33	20.72	19.69	15.79	8.81
Retained Earnings	-168.44	-166.1	-150.36	-118.17	-79.17	-54.75
Shareholders' Equity	-25.6	-25.08	-12.96	12.51	47.61	28.07
Total Liabilities & Equity	1.01	0.76	7.53	22.11	52.48	29.82
Total Debt	4.94	4.77	0.57	0.14	0.28	0.39
Net Cash (Debt)	-4.37	-4.51	5.44	19.67	49.5	27.48
Net Cash Growth	-	-	-72.33%	-60.26%	80.13%	746.40%
Net Cash Per Share	-	-	0.02	0.07	0.18	0.11
Book Value	-25.6	-25.08	-12.96	12.51	47.61	28.07
Book Value Per Share	-	-	-0.04	0.04	0.17	0.11
Tangible Book Value	-25.6	-25.08	-12.96	12.2	47.09	27.35
Tangible Book Value Per Share	-	-	-0.04	0.04	0.17	0.11

Updated Jan 31, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.